Matching articles for "Shingrix"
Influenza Vaccine for 2024-2025
The Medical Letter on Drugs and Therapeutics • September 16, 2024; (Issue 1711)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season are
listed in Table 2.
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • October 16, 2023; (Issue 1687)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • October 17, 2022; (Issue 1661)
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • October 17, 2022; (Issue 1661)
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Expanded Table: Some Vaccines for Adults (online only)
The Medical Letter on Drugs and Therapeutics • October 17, 2022; (Issue 1661)
...
Influenza Vaccine for 2022-2023
The Medical Letter on Drugs and Therapeutics • October 3, 2022; (Issue 1660)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2022-2023...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2022-2023 season
are listed in Table 2.
Influenza Vaccine for 2021-2022
The Medical Letter on Drugs and Therapeutics • October 4, 2021; (Issue 1634)
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication.1 Available influenza vaccines for the
2021-2022 season are listed in Table...
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication.1 Available influenza vaccines for the
2021-2022 season are listed in Table 2.
In Brief: Shingrix for Immunocompromised Adults
The Medical Letter on Drugs and Therapeutics • August 23, 2021; (Issue 1631)
The FDA has licensed the adjuvanted, recombinant
varicella zoster virus (VZV) vaccine Shingrix (GSK) for
prevention of herpes zoster (shingles) in adults of any
age who are or will be at elevated risk...
The FDA has licensed the adjuvanted, recombinant
varicella zoster virus (VZV) vaccine Shingrix (GSK) for
prevention of herpes zoster (shingles) in adults of any
age who are or will be at elevated risk because of disease-
or therapy-induced immunodeficiency or immunosuppression.
Shingrix has been licensed for herpes
zoster prevention in adults ≥50 years old since 2017.1
It is the only VZV vaccine currently available in the US;
Zostavax, a live-attenuated VZV vaccine, was withdrawn
from the market in 2020.
Influenza Vaccine for 2020-2021
The Medical Letter on Drugs and Therapeutics • September 21, 2020; (Issue 1607)
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness...
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness and symptoms
that might be confused with those of COVID-19.
Available vaccines and recommendations for specific
patient populations for the 2020-2021 season are listed
in Tables 2 and 3. Lower rates of influenza illness have
been observed this season in the Southern Hemisphere,
probably because of masking, social distancing, school
closures, and travel restrictions.
Influenza Vaccine for 2019-2020
The Medical Letter on Drugs and Therapeutics • October 21, 2019; (Issue 1583)
Annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a contraindication. Available vaccines and
recommendations for specific patient populations for
the...
Annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a contraindication. Available vaccines and
recommendations for specific patient populations for
the 2019-2020 season are listed in Tables 2 and 3.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • May 7, 2018; (Issue 1546)
The US Advisory Committee on Immunization Practices
(ACIP) recommends routine use of the following
vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with...
The US Advisory Committee on Immunization Practices
(ACIP) recommends routine use of the following
vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular
pertussis (Tdap), measles/mumps/rubella (MMR),
varicella (VAR), herpes zoster (RZV; ZVL), human
papillomavirus (HPV), and pneumococcal conjugate
(PCV13) and polysaccharide (PPSV23) vaccines. For
adults with certain medical conditions or occupational,
behavioral, or other risk factors, hepatitis A (HepA),
hepatitis B (HepB), meningococcal (MenACWY; MenB),
and Haemophilus influenzae type b (Hib) vaccines are
also recommended. Recommendations for vaccination
against seasonal influenza and vaccination of travelers
are reviewed separately.
Expanded Table: Some Vaccines Recommended for Use in Adults (online only)
The Medical Letter on Drugs and Therapeutics • May 7, 2018; (Issue 1546)
...
View the Expanded Table: Some Vaccines Recommended for Use in Adults
Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine
The Medical Letter on Drugs and Therapeutics • December 4, 2017; (Issue 1535)
The FDA has approved an adjuvanted, recombinant
varicella zoster virus (VZV) vaccine (Shingrix – GSK)
for prevention of herpes zoster (shingles) in adults ≥50
years old. Shingrix is the second herpes...
The FDA has approved an adjuvanted, recombinant
varicella zoster virus (VZV) vaccine (Shingrix – GSK)
for prevention of herpes zoster (shingles) in adults ≥50
years old. Shingrix is the second herpes zoster vaccine
to be approved in the US; Zostavax, a live-attenuated
VZV vaccine approved for the same indication, has been
available since 2006.